GenoFocus Inc Cash Flow Conversion Efficiency
GenoFocus Inc cash flow conversion efficiency. Based on the latest financial reports, GenoFocus Inc (187420) has a cash flow conversion efficiency ratio of -0.015x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-821.53 Million ≈ $-556.74K USD) by net assets (₩53.43 Billion ≈ $36.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GenoFocus Inc (2014–2025)
Cash flow conversion efficiency of GenoFocus Inc from 2014 to 2025. This chart illustrates how GenoFocus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GenoFocus Inc (187420) stock price for real-time trading data and today's change.
GenoFocus Inc Cash Flow Conversion Ratio Explained
GenoFocus Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GenoFocus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GenoFocus Inc ranked by their cash flow conversion efficiency. Also see GenoFocus Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Australian Unity Office Fund
AU:AOF
|
-0.006x |
|
Sino Tactful Co Ltd
TWO:5481
|
-0.014x |
|
Krynica Vitamin SA
WAR:KVT
|
0.004x |
|
MODULIGHT OY EO 1
F:78W
|
0.001x |
|
Decidr Ai Industries Ltd
AU:DAI
|
-0.082x |
|
Intellicheck Mobilisa Inc
NASDAQ:IDN
|
0.080x |
|
MeVis Medical Solutions AG
XETRA:M3V
|
0.005x |
|
Caprice Resources Limited
F:C3F
|
-0.006x |
Annual Cash Flow Conversion Efficiency for GenoFocus Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of GenoFocus Inc from 2014 to 2025. Review GenoFocus Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩54.75 Billion ≈ $37.10 Million |
₩3.50 Billion ≈ $2.37 Million |
0.064x | -47.00% |
| 2024-12-31 | ₩23.77 Billion ≈ $16.11 Million |
₩2.87 Billion ≈ $1.95 Million |
0.121x | +166.11% |
| 2023-12-31 | ₩26.36 Billion ≈ $17.87 Million |
₩-4.82 Billion ≈ $-3.26 Million |
-0.183x | +7.37% |
| 2022-12-31 | ₩23.89 Billion ≈ $16.19 Million |
₩-4.71 Billion ≈ $-3.19 Million |
-0.197x | -191.01% |
| 2021-12-31 | ₩35.28 Billion ≈ $23.91 Million |
₩-2.39 Billion ≈ $-1.62 Million |
-0.068x | -9.88% |
| 2020-12-31 | ₩39.77 Billion ≈ $26.95 Million |
₩-2.45 Billion ≈ $-1.66 Million |
-0.062x | -1818.94% |
| 2019-12-31 | ₩52.12 Billion ≈ $35.32 Million |
₩-167.50 Million ≈ $-113.51K |
-0.003x | -112.37% |
| 2018-12-31 | ₩60.21 Billion ≈ $40.80 Million |
₩1.56 Billion ≈ $1.06 Million |
0.026x | +22.28% |
| 2017-12-31 | ₩64.22 Billion ≈ $43.52 Million |
₩1.36 Billion ≈ $924.25K |
0.021x | +157.26% |
| 2016-12-31 | ₩62.52 Billion ≈ $42.37 Million |
₩516.09 Million ≈ $349.74K |
0.008x | -91.38% |
| 2015-12-31 | ₩29.79 Billion ≈ $20.19 Million |
₩2.85 Billion ≈ $1.93 Million |
0.096x | +423.17% |
| 2014-12-31 | ₩9.66 Billion ≈ $6.55 Million |
₩-286.45 Million ≈ $-194.12K |
-0.030x | -- |
About GenoFocus Inc
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phy… Read more